Evidence map›Paper›PMID 36425497›Full record

ArticleChemical science2022

Isobactins:

Chelsea R Jones, Gretchen Guaglianone, Grant H Lai, James S Nowick

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chemical science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Investigation of Isobactin Analogues of Teixobactin.ACS medicinal chemistry letters · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Chelsea R JonesDepartment of Chemistry, University of California, Irvine Irvine California 92697 USA jsnowick@uci.edu.ORCID https://orcid.org/0000-0002-8347-6885
Gretchen GuaglianoneDepartment of Chemistry, University of California, Irvine Irvine California 92697 USA jsnowick@uci.edu.ORCID https://orcid.org/0000-0002-5189-2550
Grant H LaiDepartment of Chemistry, University of California, Irvine Irvine California 92697 USA jsnowick@uci.edu.ORCID https://orcid.org/0000-0001-8620-3113
James S NowickDepartment of Chemistry, University of California, Irvine Irvine California 92697 USA jsnowick@uci.edu.ORCID https://orcid.org/0000-0002-2273-1029
University of California, Irvine · US

Funding

Amyloidogenic AntibioticsR21AI156565 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI NOWICK, JAMES S · 2021 to 2022
$403k
NIAID NIH HHS R21 AI156565
6 · The paper itself

Abstract

The antibiotic teixobactin is a promising drug candidate against drug-resistant pathogens, such as MRSA and VRE, but forms insoluble gels that may limit intravenous administration.

Identifiers

PMID36425497
PMCPMC9667932
OpenAlexW4310332163

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.